<![CDATA[Overview of Obstructive Sleep Apnea]]>

OSA is a highly prevalent but frequently underdiagnosed condition that significantly impacts patients' quality of life and long-term health outcomes. Despite affecting nearly 1 billion adults between the ages of 30 and 69 globally, many...

Pfizer strikes ‘most favoured nation’ drug deal with White House

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration has...

CDSCO approves Danish firm Novo Nordisk’s injection for type-2 diabetes patients

New Delhi, Sep 30 (PTI) India’s drug regulator Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic (semaglutide injection) manufactured by Danish pharma company Novo Nordisk for use in adults with type-2 diabetes. According to...

Providers need to ‘see the person, not the task’

There is a wave of change accompanying the new Aged Care Act on 1 November, but the sector needs to adapt to the complexity and prioritise a human-centred approach, Saviour Buhagiar, Uniting NSW.ACT director of senior services says. This requires...

Ozempic gets green light for diabetes in India, Mystery illness kills 14 kids in Nagpur, Chhindwara

In this segment of 5 Live, the focus is on the Indian drug regulator CDSCO's approval of the blockbuster drug Ozempic. It is cleared for treating type 2 diabetes and reducing risks of serious heart and kidney problems, but explicitly not for...

Act fast in heart attack emergencies: Subtle symptoms to recognise

Every year, thousands of Indians die from heart attacks not because treatment is unavailable, but because help is delayed. The "golden hour", which is the first 60 to 90 minutes after symptoms begin, is crucial. Acting quickly in that window can...

Pluto Health expanding payer partnerships to address care gaps

The company now has relationships with Medicare, Medicaid, and major commercial plans. Artificial Intelligence-enabled health services company Pluto Health is partnering with payers and expanding its payer relationships, in an effort to extend its...

From shaving cuts to sun damage: Key health steps for men's skin

For years, skincare aisles have been split into "men’s" and "women’s" sections, with packaging, fragrances, and labels designed to appeal to one gender or the other. This marketing tactic has fueled the misconception that men need an entirely...

Indian diet contains 62% carbs, linked to rising diabetes, obesity: ICMR

A recent nationwide study by the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB), has found that changing dietary habits among Indians are closely associated with rising rates of diabetes and obesity. The survey covered 1,21,077...

FDA’s Approval of Remibrutinib for CSU, With Giselle Mosnaim, MD

The US Food and Drug Administration (FDA) has approved remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, for adults with chronic spontaneous urticaria (CSU).1,2 The approval, announced on September 30, 2025, by Novartis, provides...

Discussing Remibrutinib Following FDA Approval for CSU, With Adam Friedman, MD

Following the US Food and Drug Administration (FDA) approval of remibrutinib for adult patients with chronic spontaneous urticaria (CSU), the HCPLive team spoke with Adam Friedman, MD, on the approval and its significance for patients and...

Pfizer Reaches Landmark Deal with Trump Administration to Lower Medicaid Drug Costs

By Emmanuel Ogbonna Pfizer has reached an agreement with the Trump administration to reduce the cost of prescription drugs for Medicaid patients, a move President Donald Trump hailed Tuesday as a breakthrough in his push to make medications more...

FDA Approves Remibrutinib for Chronic Spontaneous Urticaria

The US Food and Drug Administration (FDA) approved remibrutinib (Rhapsido), a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, for adults with chronic spontaneous urticaria (CSU).1 Novartis announced the approval on September 30, 2025....

Pfizer’s $70B US Investment Deal with Trump Dodges Tariffs, Cuts Prices

In a move that underscores the Trump administration’s aggressive push to reshape the pharmaceutical industry, Pfizer Inc. has struck a landmark deal to avert steep tariffs while committing to substantial domestic investments and price reductions....

Australian pharmaceutical industry urged to ‘put the boot’ back into Albanese amid Trump tariffs

NSW Independent MLC Tania Mihailuk questions whether Prime Minister Anthony Albanese is looking out for the interests of Australian industries. This comes amid US President Donald Trump’s 100 per cent tariffs on pharmaceuticals. “It doesn’t seem...

<![CDATA[2025 SCRS Global Site Solutions Summit: Why Collaboration and Feedback Loops Are Essential in Clinical Research]]>

ACT: What have been some of your key takeaways from the event so far? Bechtel: Key takeaways from the event: We've talked a lot about how important communication and collaboration are. We've moved from this era where, “We need to communicate. We...

COVID vaccines may have averted thousands of hospital stays in infants, pregnant women over 18 months

A US modeling study published yesterday in JAMA Pediatrics estimates that vaccinating pregnant women against COVID-19 prevented 7,000 hospitalizations in infants and 3,000 in pregnant women from January 2024 to May 2025. The Stanford...

Pfizer shares jump 7% after deal with Trump earns three-year tariff reprieve

Pfizer Inc. secured a reprieve from President Donald Trump’s long-threatened tariffs on the pharmaceutical industry Tuesday by agreeing to slash some of its drug prices by up to 85% and selling directly to the American public, a move other major...

Business confidence crashes to record low as bosses demand 'credible plan' to kick-start floundering economy

Business confidence has plunged to a record low as tax fears stifle sentiment and hold back growth, a damning new poll has revealed. The Chancellor was urged to come up with a ‘more coherent and credible plan’ for the economy after the findings by...

Evidence of herd immunity 17 years after HPV vaccination

In a new study in JAMA Pediatrics, population-level effectiveness and herd immunity were robust 17 years after human papillomavirus (HPV) vaccine introduction, even in sexually experienced adolescent girls and young women at relatively high risk...